President of the Executive Committee and Chief Science Officer
Lars Peter Brunse
Executive Vice President and Chief Production Officer
Executive Vice President and Chief Medical Officer
Executive Vice President and Chief People and Values Officer
Executive Vice President and Chief Commercial Officer
Secretary to the Executive Committee and Chief Legal Officer
Executive Vice President and Chief Financial Officer
Per joined Ferring Pharmaceuticals in 2015 and was appointed President from January 1st 2019. He also holds the role of Chief Science Officer, with responsibility for overseeing Ferring's Research, Development & Regulatory activities.
Prior to joining Ferring, Per held executive and senior leadership positions at Novo Nordisk and AstraZeneca in research, medical and clinical development roles.
For over 30 years, Per has been investigating and evolving microbiome science, holding faculty positions at some of the world’s leading institutions to advance research in this field. During his career, he has held the role of Associate Professor at the Karolinska Institute, Sweden and the Washington University School of Medicine, USA.
Per is a qualified medical doctor and also has a Ph.D. in Biochemistry and Clinical Chemistry.
Lars Peter Brunse
Mr Lars Peter Brunse joined Ferring as Associate Director in 2000 and was shortly after promoted to Senior Vice President, Technical Operations and Logistics. He has led the expansion of Ferring’s manufacturing capability with the development of an additional nine state-of-the-art production sites, and extended the company’s product supply network from approximately 500 employees in the year 2000 to over 1,600 today. Prior to joining Ferring, Lars Peter worked at Novo Nordisk in Manufacturing, Operational Excellence, and Quality Assurance Management.
Lars Peter holds a Master degree in Pharmaceutical Sciences from University of Copenhagen.
Professor Klaus Dugi joined Ferring in October 2017. He is responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance.
Prior to joining Ferring, Klaus held various leadership roles at Boehringer Ingelheim, including Vice President Global Medical Affairs, Chief Medical Officer, and, most recently, Managing Director UK & Ireland.
A Professor of Medicine, with a specialty in Internal Medicine, Klaus continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes.
Ms. Jean Duvall joined Ferring in November 2006 and is responsible for all legal activities on a global basis.
Prior to her arrival at Ferring, Jean was General Counsel at Elan Corporation, plc. She has a Bachelor of Science degree from Case Western Reserve University and a Juris Doctor degree from Ohio State University.
Mr. Aaron Graff joined Ferring in 2002 as Vice President Global Marketing, Business Development, and Medical Affairs, based in Copenhagen, Denmark. After leading the acquisition and integration of Israeli biopharmaceutical company BTG in 2005, he relocated his team to the newly established Ferring International Center in Saint-Prex, Switzerland, where he was promoted to Senior Vice President, Asia Region and Global Marketing. Since 2010, Aaron has led Ferring’s U.S. operations from its U.S headquarters in New Jersey, first as Chief Operating Officer and since 2016 as Chief Executive Officer. Prior to joining Ferring, Aaron worked at Bristol-Myers Squibb for over 17 years.
Aaron has a Bachelor of Business Administration and Finance from University of Michigan, and an MBA from NYU Stern School of Business.
Mr. Dominic Moorhead joined Ferring in July 2017 as Chief Financial Officer (CFO).
Dominic has 30 years’ finance and business experience in the life sciences industry. For the past year, he has been a strategic advisor to executives and investors in biotech. Previously, he worked for Takeda Pharmaceuticals as Global Financial Controller, and CFO of the international business following the acquisition of Nycomed. Prior to this Dominic worked for Hoffmann-La Roche, where he was CFO of the Pharma Division for nine years during a period of transformation and growth. He was engaged in numerous strategic initiatives and business transactions, as well as their operational implications, culminating in the privatisation of Genentech in the U.S. in 2009.
Dominic has an ACA from Institute of Chartered Accountants in England and Wales and a BSc in Chemistry from the University of Nottingham.